Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:00 2024-06-06 am EDT 		5-day change 1st Jan Change
290 GBX -0.34% Intraday chart for HUTCHMED (China) Limited -2.68% +2.47%
Jun. 03 HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine CI
May. 24 HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,356 4,555 6,141 2,698 3,074 3,165 - -
Enterprise Value (EV) 1 3,165 4,147 5,156 2,085 2,870 2,910 2,782 2,812
P/E ratio -31.5 x -34.9 x -28.7 x -7.43 x 30 x -29.2 x 266 x 29.9 x
Yield - - - - - - - -
Capitalization / Revenue 16.4 x 20 x 17.2 x 6.33 x 3.67 x 4.58 x 3.73 x 3.04 x
EV / Revenue 15.4 x 18.2 x 14.5 x 4.89 x 3.42 x 4.21 x 3.28 x 2.7 x
EV / EBITDA -22.4 x -21.8 x -16.1 x -5.23 x 108 x -19.5 x -54.6 x 126 x
EV / FCF -35.4 x - -23.4 x -6.83 x 15.4 x -14.9 x -68.1 x 64.3 x
FCF Yield -2.83% - -4.28% -14.6% 6.5% -6.73% -1.47% 1.56%
Price to Book 11.7 x 9.46 x 6.28 x 4.52 x 4.29 x 1.58 x 1.52 x 1.24 x
Nbr of stocks (in thousands) 665,965 724,205 856,470 845,074 853,410 853,652 - -
Reference price 2 5.039 6.290 7.170 3.193 3.602 3.708 3.708 3.708
Announcement Date 3/3/20 3/4/21 3/3/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 204.9 228 356.1 426.4 838 690.7 849 1,043
EBITDA 1 -141.4 -190.6 -321.1 -399 26.58 -149 -50.95 22.28
EBIT 1 -146.4 -196.7 -328.3 -407.7 18.38 -154 -62.42 34.41
Operating Margin -71.45% -86.27% -92.19% -95.61% 2.19% -22.3% -7.35% 3.3%
Earnings before Tax (EBT) 1 -141.1 -189.7 -215.7 -410.4 58.31 -139.3 -28.61 62.56
Net income 1 -106 -125.7 -194.6 -360.8 100.8 -105.4 0.3699 97.73
Net margin -51.75% -55.15% -54.66% -84.62% 12.03% -15.26% 0.04% 9.37%
EPS 2 -0.1600 -0.1800 -0.2500 -0.4300 0.1200 -0.1269 0.0140 0.1241
Free Cash Flow 1 -89.48 - -220.6 -305.3 186.6 -195.9 -40.87 43.73
FCF margin -43.67% - -61.95% -71.59% 22.27% -28.37% -4.81% 4.19%
FCF Conversion (EBITDA) - - - - 702.15% - - 196.32%
FCF Conversion (Net income) - - - - 185.2% - - 44.75%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/3/20 3/4/21 3/3/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 102.7 106.8 121.2 157.4 198.8 202 224.4 532.9 305.1 321.9 349.3 404.9 414.8
EBITDA - - - - - - - - - - - - -
EBIT 1 - -78.16 -118.5 -143.7 -184.6 -196.8 -210.9 111.7 -93.28 -65.2 -79.6 -61.44 -67.52
Operating Margin - -73.21% -97.77% -91.34% -92.86% -97.38% -94.02% 20.95% -30.57% -20.25% -22.79% -15.18% -16.28%
Earnings before Tax (EBT) 1 - -76.58 -113.2 -140.4 -75.29 -200.6 -209.8 - -78.78 -39.7 -103.1 - -
Net income 1 - -49.69 -76.04 -102.4 -92.25 -162.9 -198 - -67.77 -52.6 -64.3 - -
Net margin - -46.55% -62.73% -65.07% -46.41% -80.61% -88.24% - -22.21% -16.34% -18.41% - -
EPS - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/3/20 7/30/20 3/4/21 7/28/21 3/3/22 8/1/22 2/28/23 7/31/23 2/28/24 - - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 190 408 985 613 204 256 383 353
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -89.5 - -221 -305 187 -196 -40.9 43.7
ROE (net income / shareholders' equity) -31.3% -32.6% -26.5% -45.2% 13.8% -12.9% -0.93% 12.4%
ROA (Net income/ Total Assets) -21.3% -21.1% -18.6% -30% 7.88% -9.08% -2.13% 5.66%
Assets 1 498.6 594.6 1,048 1,201 1,280 1,161 -17.36 1,728
Book Value Per Share 2 0.4300 0.6700 1.140 0.7100 0.8400 2.350 2.430 2.990
Cash Flow per Share 2 -0.1200 -0.0900 -0.2600 -0.3200 0.2500 -0.1400 -0.0400 0.1000
Capex 1 8.57 7.95 16.4 36.7 32.6 27.5 23.2 26.8
Capex / Sales 4.18% 3.49% 4.61% 8.6% 3.89% 3.97% 2.73% 2.57%
Announcement Date 3/3/20 3/4/21 3/3/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for HUTCHMED (China) Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.708 USD
Average target price
5.719 USD
Spread / Average Target
+54.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HUTCHMED (CHINA) LIMITED Stock HUTCHMED (China) Limited
+2.47% 3.17B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.64% 749B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.42% 605B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.58% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.72% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.78% 292B
NOVARTIS AG Stock Novartis AG
+11.92% 216B
ROCHE HOLDING AG Stock Roche Holding AG
-2.62% 214B
PFIZER, INC. Stock Pfizer, Inc.
+0.03% 167B
AMGEN INC. Stock Amgen Inc.
+6.13% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HCM Stock
  4. Financials HUTCHMED (China) Limited